NCT06198751View on ClinicalTrials.gov

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

May 8, 2025

Study Completion Date

February 29, 2028

Conditions
Breast Cancer
Interventions
DRUG

6.0 mg/kg of TQB2102 for injection

TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.

DRUG

7.5 mg/kg of TQB2102 for injection

TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.

Trial Locations (7)

110801

Liaoning Cancer Hospital & Institute, Shenyang

150040

Harbin medical university cancer hospital, Harbin

200030

Fudan University Shanghai Cancer Center, Shanghai

350014

Fujian Cancer Hospital, Fuzhou

400030

Chongqing Cancer Hospital, Chongqing

410013

Hunan Cancer Hospital, Changsha

550001

Guizhou Cancer Hospital, Guiyang

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY